Antidepressants use is associated with overall survival improvement of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan

A large population-based cohort study

Wei-Tai Shih, MD, Pei-Rung Yang, MD, MS, Ko-Jung Chen, MPH, Yao-Hsu Yang, MD, PhD, Mong-Liang Lu, MD, MPH, Vincent Chin-Hung Chen, MD, PhD, Yi-Chia Shen, MD

Abstract
To determine whether exposure to antidepressants (ATDs) results in improved overall survival (OS) of patients with gastric cancer (GC) after surgery, we conducted a large cohort study and considered confounding factors that might affect the research outcomes.

Patients who received a new diagnosis of GC and received surgery and chemotherapy between 1999 and 2008 were recruited and were classified into different groups based on the ATD level used. The association between the OS of patients with GC after surgery with different levels of ATD use, and the hazard ratio with comorbidities at different ATD use levels were compared.

According to Kaplan–Meier method, the more of an ATD was taken, the longer the OS and a dose-dependent relationship was discovered in the OS curve; the adjusted HRs were 0.76 (95% confidence interval [CI] = 0.68–0.84) and 0.48 (95% CI = 0.41–0.57) for ATD users taking a cumulative defined daily dose (cDDD) of 28–167 and ≥168, respectively. Sensitivity analyzes were performed to investigate the effect of various comorbidities on OS with different degrees of ATD use and the results remained consistent among the varying models. Additionally, the effect of ATD use still exhibited a dose-dependent relationship in distinct stratifications for sex and age.

The OS for patients with GC after surgery and chemotherapy improved with ATD use, and a dose-dependent relationship was discovered in this study. Further studies on the association between OS of GC and ATD use are required.

Abbreviations: ATD = antidepressant, cDDD = cumulative defined daily dose, CI = confidence interval, CIRPD = catastrophic illness registry patient database, DDD = defined daily dose, GC = gastric cancer, HR = hazard ratio, NHIRD = National Health Insurance Research Database, OS = overall survival, SSRI = selective serotonin reuptake inhibitor.

Keywords: antidepressant, gastric cancer, overall survival, population-based cohort study

1. Introduction

According to global cancer statistics from 2018, gastric cancer (GC) ranks as the fifth most commonly diagnosed cancer worldwide (fifth and eighth in incidence for men and women, respectively), causing more than 1,000,000 new cases yearly; there were 783,000 deaths from GC in 2018, and GC was the fourth and sixth leading cause of cancer death in men and women, respectively.[1] The age-standardized 5-year overall survival rate is 20% to 40% globally; however, a considerable variation exists in this percentage in Asia, with survival rate being 69% in South Korea and 60% in Japan.[2] The incidence of GC exhibits clear geographic differences; it is markedly high in Asia and generally low in Northern America, Northern Europe, and Africa.[1] This regional variation partly reflects different ethics, dietary patterns, food storage methods, and prevalence of Helicobacter pylori infection.[3] In 1994, the International Agency for Research on Cancer stated that H. pylori is a group I human carcinogen responsible for gastric adenocarcinoma.[4]

Two types of classification system have been used for GC: the more widely used TNM system is based on the American Joint Committee on Cancer and Union for International Cancer Control classification, eighth edition; the other classification, which originated in Japan, classifies GC according to its anatomic location, especially lymph node stations. Locally restricted tumor (stages I to III) is generally curable; by contrast, patients with
advanced disease (stage IV) may be administered palliative treatment according to their functional status and symptoms. The survival rate in endoscopic resection versus surgical resection is similar.[5] Complete tumor removal results in superior survival for patients with localized GC, especially when it is combined with adjuvant or perioperative chemotherapy.[6,7]

GC is the fifth most commonly diagnosed cancer in Taiwan, and 3973 Taiwanese cases were diagnosed in 2012. The age-standardized incidence was 15.03 per 100,000 person-years; in addition, GC was reported to be the sixth greatest cause of cancer-related death in Taiwan, and the standardized mortality rate of patients diagnosed with GC was 6.4 per 100,000 person-years in 2012.[8] According to the Taiwanese Cancer Registry Annual Report 2016, stages Ib, II, and III accounted for more than half of patients with GC, and most patients received surgery plus adjuvant chemotherapy.

Although the 5-year survival rate of GC has been improving gradually, the occurrence of depression after cancer diagnosis has been increasing. Cancer is a common risk factor for emotional interference, especially depression.[9] Considerable evidence has been obtained showing that depression is associated with poor outcome and decreased quality of life in patients with cancer.[10] Hawkins et al reported that the incidence of taking medication for anxiety or depression was almost 2 times higher in the population of individuals who had survived cancer than the total population because of psychological suffering or physical burden caused by cancer.[11] In a nationwide study, Hu et al found that there was a higher incidence (adjusted hazard ratio [HR] = 1.54, 95% confidence interval [CI] = 1.39–1.70, P < .001) of newly diagnosed depressive disorder after GC diagnosis in a GC cohort than in a matched cohort.[12] Shoval et al reported that higher adherence to antidepressant drugs (ATDs) was associated with lower all-cause mortality in a large nationwide cohort of patients with cancer.[13] The scope of this study is to determine whether the overall survival (OS) of patients with GC after surgery and adjuvant chemotherapy is superior after exposure to ATDs. In order to do that we employed a large cohort from the Taiwan National Health Insurance Research Database (NHIRD) and considered confounding factors that might affect outcomes.

2. Materials and methods

2.1. Source of study population

The population of this study was derived from the NHIRD, which covers almost the entire population of Taiwan of up to 23.7 million. Because of its strict secrecy guidelines, the NHIRD contains no identifiable personal information. This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital, Chiayi, Taiwan.

2.2. Inclusion and exclusion criteria

Patients in the Catastrophic Illness Registry Patient Database (CIRPD) who received a new diagnosis of GC according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM code 151.xx) and received surgery and chemotherapy between 1999 and 2008 were enrolled as study patients. Patients with other cancer before the GC diagnosis, who did not undergo surgery or chemotherapy, who underwent surgery after neoadjuvant chemotherapy, who were aged less than 18 years, and with incomplete data were excluded.

2.3. Demographic data

Patients’ demographic data, namely sex, age, level of urbanization, income level (New Taiwan Dollars per month), comorbidities, and chemotherapy regimen, were retrieved from the NHIRD. Comorbidities, namely diabetes mellitus, hypertension, alcoholism, smoking-related disorder, chronic renal failure, and liver cirrhosis, were analyzed. Chemotherapy regimens were classified into 4 groups:

1. epirubicin based,
2. mitomycin based,
3. taxanes, and
4. others (Table 1).

2.4. Antidepressant drug exposure

The source of exposure to ATD types and dosages were derived from the NHIRD, and in this study, ATDs were classified into 4 subtypes: selective serotonin reuptake inhibitor (SSRI), serotonin and norepinephrine reuptake inhibitor, tricyclic antidepressant, and others (combined serotonin antagonist and reuptake inhibitor, norepinephrine–dopamine reuptake inhibitor, and mirtazapine and monoamine oxidase inhibitor). The defined daily dose (DDD), defined by the World Health Organization, is the unit used for calculating a prescribed amount of a drug and is assumed the average maintenance dose of a drug consumed for its main indication per day. Using the following formula, we could compare different types of ATD on the basis of the same standard: (total amount of drug)/(amount of drug in DDD) = number of DDDs. The cumulative DDD (cDDD), which indicates the total exposure to an ATD, was calculated as the predictive sum of the dispensed DDD of any ATD and used to compare the drugs’ positive effects on the survival of patients with GC after surgery.[14]

To determine the dose-dependent relationship, cDDD was categorized into 3 gradients:

1. cDDD < 28,
2. cDDD = 28–167, and
3. cDDD ≥ 168. Patients who took a cDDD of less than 28 were defined as ATD nonusers.

2.5. Matched cohort

To understand the effect of ATDs on the OS of patients with GC after surgery, propensity scores were used to estimate the probabilities of assigning patients taking ATDs with the variables as sex, age, level of urbanization, income level, comorbidities, and chemotherapy regimen. ATD users and nonusers were matched with propensity scores in the ratio of 1:4. The baseline demographic data are presented in Table 1.

2.6. Statistical analysis

Categorical variables were examined using the Chi-Squared test, and continuous variables were assessed using the t-test. To assess the association between the OS of patients with GC after surgery and the level of ATD use, the Kaplan–Meier method was used and the log-rank test employed to examine differences in survival.
among ATD users. Cox proportional hazard models were used to compare HRs with 95% CIs after adjusting for sex, age, level of urbanization, and income level. A P value of < .05 or 95% CI was considered statistically significant. All analyzes were performed using SAS statistical software (version 9.4; SAS Institute, Cary, NC, USA).

2.7. Sensitivity analysis
To compute the effects of different comorbidities on OS, cDDD was stratified into cDDD of 28–167 and cDDD ≥ 168. Subgroups were formed from baseline characteristics, such as sex and age, to verify the consistency between different levels of ATD use and OS.

3. Results
According to the CIRPD, 33,256 patients received a new diagnosis of GC between 1999 and 2008. Of these, 1331 were excluded due to cancer before GC diagnosis. Patients who underwent no surgery (N = 12,067), no chemotherapy (N = 8,786), or surgery after neoadjuvant chemotherapy (N = 250) were also excluded. Another 205 patients were excluded because of age less than 18 years (N = 2) and incomplete data (N = 203). The study cohort consisted of 10,617 patients—1007 ATD users and 9610 ATD nonusers. After propensity score matching in the ratio of 1:4, the number of ATD users and nonusers was 1007 and 4028, respectively (Fig. 1). No significant differences existed in baseline demographic characteristics between ATD users and nonusers (Table 1).

This study enrolled 5035 patients who were followed up for a total of 27,438.1 person-years. The mean follow-up duration was 5.1 years for ATD nonusers, 6.3 years for those taking ATDs at a cDDD of 28–167, and 7.5 years for those taking ATDs at a cDDD of ≥ 168. A total of 3314 deaths occurred during the 10-year follow-up period; of these, 2740 occurred in the ATD nonuser group. The incidence of death was 13,234.7 per 100,000 person-years in the ATD nonuser group and 9920.5 and 6216.7 per 100,000 person-years in the subgroups of cDDD of 28 to 167 and cDDD ≥ 168, respectively (Table 2). According to Kaplan–Meier method, the more of an ATD was taken, the longer the OS. The log-rank test revealed a significant difference in the survival curve (Fig. 2). Furthermore, a dose-dependent relationship was discovered in the OS curve; the adjusted HRs were 0.76 (95% CI = 0.68–0.84) and 0.48 (95% CI = 0.41–0.57) for ATD users taking a cDDD of 28 to 167 and ≥ 168, respectively. To investigate the effect of various comorbidities on OS with varying degrees of ATD use, sensitivity analyses were performed. The

Table 1
Demographic characteristics of ATD users and ATD nonusers among GC patients after surgery and adjuvant chemotherapy in Taiwan during 1999–2008 in the matched cohort.

|                          | ATD user (N = 1007) | ATD nonuser (N = 4028) | P value |
|--------------------------|---------------------|------------------------|---------|
|                          | n       | %     | n       | %     |         |
| Sex                      |         |       |         |       |         |
| Female                   | 426     | 42.3  | 1685    | 41.8  | .7861   |
| Male                     | 581     | 57.7  | 2343    | 58.2  |         |
| Age (year-old)           |         |       |         |       |         |
| 18–64                    | 531     | 52.7  | 2054    | 51.0  | .3237   |
| ≥ 65                     | 476     | 47.3  | 1974    | 49.0  |         |
| Mean (SD)                | 62.0 (12.9) | .8017 | 62.2 (13.5) | .6336 |
| Urbanization             |         |       |         |       |         |
| Very high                | 296     | 29.4  | 1125    | 27.9  |         |
| High                     | 479     | 47.6  | 1954    | 48.5  |         |
| Moderate                 | 170     | 16.9  | 707     | 17.6  |         |
| Low                      | 62      | 6.2   | 242     | 6.0   |         |
| Income level (NTD/ month) |        |       |         |       | .8220   |
| 0                        | 181     | 18.0  | 678     | 16.8  |         |
| 1–15840                  | 186     | 18.5  | 763     | 18.9  |         |
| 15841–25000              | 458     | 45.5  | 1871    | 46.5  |         |
| ≥ 25000                  | 182     | 18.1  | 716     | 17.8  |         |
| Comorbidities            |         |       |         |       |         |
| Diabetes mellitus        | 227     | 22.5  | 901     | 22.4  | .9058   |
| Hypertension             | 456     | 45.3  | 1847    | 45.9  | .7449   |
| Alcoholism               | 23      | 2.3   | 97      | 2.4   | .8173   |
| Smoking-related disorder | 110     | 10.9  | 416     | 10.3  | .5803   |
| Chronic renal failure    | 21      | 2.1   | 95      | 2.4   | .6054   |
| Liver cirrhosis          | 27      | 2.7   | 114     | 2.8   | .7978   |
| Chemotherapy regimen     |         |       |         |       | .9205   |
| Epirubicin-based         | 111     | 11.0  | 432     | 10.7  |         |
| Mitomycin-based          | 130     | 12.9  | 533     | 13.2  |         |
| Taxanes                  | 16      | 1.6   | 54      | 1.3   |         |
| Others                   | 750     | 74.5  | 3009    | 74.7  |         |

ATD = antidepressant, GC = gastric cancer, NTD = New Taiwan Dollars.
* 1 US $ = 32.3 NTD in 2008.
effects of different levels of ATD use on OS were found to remain consistent among the different models (Table 3). Additionally, the effect of ATD use still exhibited a dose-dependent relationship in distinct stratifications for sex and age.

4. Discussion

To our knowledge, this is the first study to explore whether an association exists between OS in early stage GC after surgery and ATD use by employing a large cohort database. The results revealed a dose-dependent association between ATD use and OS among patients with early stage GC after surgery. The findings persisted after controlling factors commonly related to GC. Hsieh et al concluded that no association existed between ATD exposure and risk of GC, but in our study, an increase in OS of GC after surgery among ATD users was confirmed, and a dose-dependent relationship was also discovered.

According to previous research, ATDs, namely SSRIs and TCAs, exhibit high apoptotic activity in human and murine neoplastic tissues and also strong effects on the cell cycle and signal transduction. Desipramine caused apoptotic cell death with suspension of cell cycle progression at either the G0/G1 phase or G2/M phase to inhibit tumor cell proliferation. Di Rosso et al reported that SSRI regulated immune function through the serotonin-dependent pathway and altered tumor cell viability. Grygier et al indicated that the inhibitory effect of fluoxetine on melanoma progression was related to elevated mitogen-induced T-cell proliferation, which partially participated in the mechanism underlying the antitumor effect of fluoxetine.

In vivo long-term administration of fluoxetine was recently demonstrated to suppress tumor growth by increasing antitumor T-cell activity. Fluoxetine has been shown to be a highly effective chemosensitizer: in vitro, its cytotoxicity was 10 to 100-fold of the anticancer drugs provided; in vivo, 12-fold enhancement of doxorubicin accumulation in tumors was achieved without changing the pharmacokinetics. With the combination of fluoxetine and doxorubicin, almost 2- to 3-fold improvement was achieved in both response and survival. In related research, fluoxetine has been shown to activate receptors overexpressed in cancer stem cells, and this finding might explain why SSRIs can lower the risk of various types of cancer. Furthermore, fluoxetine inhibited multi-drug-resistance pumps, adding the effects of multiple chemotherapies. Because of the great potential of SSRIs in cancer therapy, ATDs should be more extensively used not just for cancer-related depression but also to increase the efficacy of standardized chemotherapy regimens.

The strengths of this study have several aspects as follows. First, the data used in this research came from the NHIRD, which covers almost whole population in Taiwan rather than a small sample, helping the study avoid selection bias. Second, all patients’ diagnoses were confirmed by the CIRPD, which requires proof from tissue pathology, related images, or laboratory data and strict review by a formal committee consisting of members of the Bureau of National Health Insurance to ensure inclusion accuracy. Third, all surgical interventions, medical histories, and prescriptions were recorded in either outpatient records or hospitalization records in the NHIRD and could be analyzed and stratified by CIRPD, which requires proof. Fourth, propensity score matching was used in this research design to reduce numbers lost among ATD users/nonusers and heterogeneity among all patients.

This study has some limitations that may affect the results and interpretations of this study. First, the body mass index, which may affect the concentration of an ATD was not included in demographic data. Second, data in the CIRPD did not include

### Table 2

| ATD use    | Death | Total follow-up (person-year) | Incidence rate* | 95% CI     | Mean follow-up (year) |
|------------|-------|-------------------------------|-----------------|------------|-----------------------|
| <28 cDDD   | 2740  | 20703.2                       | 13234.7         | 12748.3    | 13739.7               | 5.1                   |
| 28-167 cDDD| 416   | 4193.3                        | 9920.5          | 9011.6     | 10921.2               | 6.3                   |
| ≥168 cDDD  | 158   | 2541.6                        | 6216.7          | 5319.1     | 7265.7                | 7.5                   |

ATD = antidepressant, cDDD = cumulative defined daily dose, CI = confidence interval.

* a per 100,000 person-years.
Table 3

Adjusted HR of OS associated with different comorbidities on cDDD levels.

| Variables                        | 28-167 cDDD          |       |       |       | ≥168 cDDD          |       |       |       |
|----------------------------------|----------------------|-------|-------|-------|-------------------|-------|-------|-------|
|                                  | HR                   | 95% CI|       |       | HR               | 95% CI|       |       |
|                                  |                      |       |       |       |                  |       |       |       |
| Main model a                     | 0.76                 | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.57  | <.0001|
| Additional covariates b          |                      |       |       |       |                  |       |       |       |
|                               |                      |       |       |       |                  |       |       |       |
| Main model+ diabetes mellitus    | 0.75                 | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.56  | <.0001|
| Main model+ hypertension         | 0.76                 | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.56  | <.0001|
| Main model+ alcoholism           | 0.76                 | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.57  | <.0001|
| Main model+ smoking-related disorder | 0.76              | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.56  | <.0001|
| Main model+ chronic renal failure| 0.76                 | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.57  | <.0001|
| Main model+ liver cirrhosis      | 0.76                 | 0.68  | 0.84  | <.0001| 0.48             | 0.41  | 0.57  | <.0001|
| Main model+ chemotherapy regimen | 0.75                 | 0.68  | 0.83  | <.0001| 0.48             | 0.41  | 0.57  | <.0001|
| Subgroup effects                 |                      |       |       |       |                  |       |       |       |
| Sex                              |                      |       |       |       |                  |       |       |       |
| Male                             | 0.78                 | 0.68  | 0.89  | .0002 | 0.51             | 0.41  | 0.62  | <.0001|
| Female                           | 0.73                 | 0.61  | 0.86  | .0002 | 0.45             | 0.35  | 0.58  | <.0001|
| Age at surgery                   |                      |       |       |       |                  |       |       |       |
| 18–64-year-old                   | 0.81                 | 0.70  | 0.94  | .0057 | 0.47             | 0.37  | 0.59  | <.0001|
| > 65-year-old                    | 0.71                 | 0.62  | 0.82  | <.0001| 0.50             | 0.40  | 0.62  | <.0001|

cDDD = cumulative defined daily dose, CI = confidence interval, HR = hazard ratio, MAOI = monoamine oxidase inhibitor, NDRI = norepinephrine-dopamine reuptake inhibitor, OS = overall survival, SARI = serotonin antagonist and reuptake inhibitor.

* a: Adjusted for all covariates (all kinds of ATD, sex age, urbanization, income).
  * b: Other: combined SARI, NDRI, Mirtazapine, MAOI.
cancer staging data; therefore, the results of this research could not be applied to all patients with GC. However, by screening according to the type of medical intervention received—that is, surgery or not and with or without a chemotherapy regimen—we could select patients ranged between stage Ib to III GC. In this study, we excluded those who did not receive surgery (stage IV) because palliative treatment was usually performed instead of curative treatment; those who did not receive chemotherapy (very early stage, such as stages 0 and Ia) because their 5-year survival rate is higher than 90%; and those who received neoadjuvant chemotherapy (debulking for primary tumor invading through the submucosa, T2 or higher). Our patients were in early stage as Ib, II, or III, which corresponded to the statistics of GC stage in Taiwan. Third, employing prescription records as data of ATD exposure may have resulted in overestimation of the cDDD level due to uncertain medical compliance, and other self-paid over-the-counter medications were not detailed in prescription records. In addition, nutritional status, which substantially influences the survival of patients with cancer, was also not noted in medical records and could not be systematically analyzed and compared.

5. Conclusion

The OS of patients with early stage GC improved with ATD use, and a dose-dependent relationship was discovered in this study. Additional studies regarding the association between the OS of GC and ATD use are required.

Acknowledgments

We would like to thank Health Information and Epidemiology Laboratory of Chang Gung Memorial Hospital, Chiayi Branch, for the comments and assistance in data analysis.

Author contributions

Conceptualization: Yao-Hsu Yang.
Data curation: Ko-Jung Chen, Yao-Hsu Yang.
Formal analysis: Ko-Jung Chen.
Methodology: Pei-Rung Yang.
Writing – original draft: Wei-Tai Shih.
Writing – review & editing: Mong-Liang Lu, Vincent Chin-Hung Chen, Yi-Chia Shen.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–75.
[3] Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030–44.
[4] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to HumansLyon 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1.
[5] Wang S, Zhang Z, Liu M, et al. Endoscopic resection compared with gastrectomy to treat early gastric cancer: a systematic review and meta-analysis. PLoS One 2015;10:e0144774.
[6] Macdonald JS, Smallley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.pdf. N Engl J Med 2001;345:725–30.
[7] Van Cutsem E, Sagare X, Topal B, et al. Gastric cancer. Lancet 2016;388:2634–48.
[8] Chiang CJ, Lo WC, Yang YW, et al. Incidence and survival of adult cancer patients in Taiwan, 2002–2012. J Formos Med Assoc 2016;115:1076–88.
[9] Smith HR. Depression in cancer patients: pathogenesis, implications and treatment (Review). Oncol Lett 2015;9:1509–14.
[10] DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101–7.
[11] Hawkins NA, Soman A, Buchanan Lunsford N, et al. Use of medications for treating anxiety and depression in cancer survivors in the United States. J Clin Oncol 2017;35:78–85.
[12] Hu LY, Liu CJ, Yeh CM, et al. Depressive disorders among patients with gastric cancer in Taiwan: a nationwide population-based study. BMC Psychiatry 2018;18:272.
[13] Shoval G, Balicer RD, Feldman B, et al. Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: a nationwide cohort study. Depress Anxiety 2019;1–9.
[14] Yang YH, Chen WC, Tsan YT, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 2015;63:1111–7.
[15] Hsieh YH, Chiu WC, Lin CF, et al. Antidepressants and gastric cancer: a nationwide population-based nested case-control study. PLoS One 2015;10:e0143686.
[16] Chilmonczyk Z, Bojarski AJ, Plic A, et al. Serotonin transporter and receptor ligands with antidepressant activity as neuroprotective and proapoptotic agents. Pharmacol Rep 2017;69:469–78.
[17] Arimochi H, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 2006;541:17–23.
[18] Di Rosso ME, Palumbo ML, Genaro AM. Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug? Pharmacol Res 2016;109:101–7.
[19] Gryger B, Arteta B, Kubera M, et al. Inhibitory effect of antidepressants on B16F10 melanoma tumor growth. Pharmacol Rep 2013;65:672–81.
[20] Peer D, Dekel Y, Melikhov D, et al. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004;64:7562–9.
[21] Radin DP, Patel P. A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors. Biomed Pharmacother 2017;87:e36–9.